Segall Bryant & Hamill LLC Takes Position in Arcutis Biotherapeutics, Inc. $ARQT

Segall Bryant & Hamill LLC purchased a new stake in shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 25,439 shares of the company’s stock, valued at approximately $609,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in ARQT. SBI Securities Co. Ltd. lifted its position in Arcutis Biotherapeutics by 325.4% during the 4th quarter. SBI Securities Co. Ltd. now owns 1,089 shares of the company’s stock valued at $32,000 after purchasing an additional 833 shares during the period. Global Retirement Partners LLC acquired a new position in Arcutis Biotherapeutics in the fourth quarter valued at approximately $35,000. EverSource Wealth Advisors LLC boosted its stake in Arcutis Biotherapeutics by 124.0% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,261 shares of the company’s stock valued at $37,000 after acquiring an additional 698 shares during the last quarter. NewEdge Advisors LLC grew its holdings in Arcutis Biotherapeutics by 209.0% during the 4th quarter. NewEdge Advisors LLC now owns 1,545 shares of the company’s stock worth $45,000 after acquiring an additional 1,045 shares during the period. Finally, Truvestments Capital LLC raised its position in shares of Arcutis Biotherapeutics by 114.2% during the 4th quarter. Truvestments Capital LLC now owns 3,012 shares of the company’s stock valued at $87,000 after acquiring an additional 1,606 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on ARQT shares. Weiss Ratings restated a “sell (d-)” rating on shares of Arcutis Biotherapeutics in a research report on Wednesday, June 24th. Wall Street Zen raised Arcutis Biotherapeutics from a “hold” rating to a “buy” rating in a research note on Sunday, July 12th. Finally, Needham & Company LLC restated a “buy” rating and set a $36.00 target price on shares of Arcutis Biotherapeutics in a report on Thursday, May 7th. Five analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $34.00.

Key Arcutis Biotherapeutics News

Here are the key news stories impacting Arcutis Biotherapeutics this week:

• Positive Sentiment: Strong revenue growth and earnings beat: Second-quarter net product revenue reached $129.9 million, up 59% from the prior-year quarter and 23% sequentially. Adjusted earnings of $0.11 per share exceeded analyst estimates ranging from $0.06 to $0.09, compared with a $0.13 loss a year earlier. Arcutis Announces Second Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: Raised 2026 sales outlook: Arcutis increased its full-year net product sales guidance to $525 million–$540 million, signaling confidence in sustained demand for ZORYVE. The company also maintained positive operating cash flow during the quarter. Arcutis Announces Second Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: Expanded growth opportunities: The FDA approved ZORYVE cream 0.3% for plaque psoriasis in children as young as two. The FDA also accepted an application for use in infants aged three to 24 months with mild-to-moderate atopic dermatitis, with a target decision date of February 23, 2027. Enrollment is complete in a Phase 2 vitiligo study, with results expected in the fourth quarter of 2026. Arcutis Announces Second Quarter 2026 Financial Results and Provides Business Update
• Neutral Sentiment: Insider sales appear administrative: Three executives sold a combined 6,560 shares at approximately $26.12 per share. The transactions were made under pre-arranged Rule 10b5-1 plans to cover tax withholding on vested equity awards, limiting their significance as a bearish signal. SEC Insider Trading Filing

Insider Activity at Arcutis Biotherapeutics

In other news, insider Masaru Matsuda sold 1,230 shares of the stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $26.12, for a total transaction of $32,127.60. Following the completion of the sale, the insider owned 126,171 shares of the company’s stock, valued at $3,295,586.52. This represents a 0.97% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Sue-Jean Lin sold 4,946 shares of the firm’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $24.38, for a total transaction of $120,583.48. Following the sale, the director owned 27,567 shares in the company, valued at approximately $672,083.46. The trade was a 15.21% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 16,894 shares of company stock worth $422,044 over the last ninety days. 9.40% of the stock is owned by corporate insiders.

Arcutis Biotherapeutics Trading Up 4.1%

NASDAQ ARQT opened at $27.10 on Thursday. Arcutis Biotherapeutics, Inc. has a one year low of $13.69 and a one year high of $31.77. The company has a debt-to-equity ratio of 0.54, a current ratio of 2.68 and a quick ratio of 2.46. The firm has a market cap of $3.39 billion, a P/E ratio of -903.03 and a beta of 1.49. The stock’s 50-day moving average is $25.87 and its 200-day moving average is $24.68.

Arcutis Biotherapeutics (NASDAQ:ARQT) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $0.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.06 by $0.05. Arcutis Biotherapeutics had a negative return on equity of 1.41% and a negative net margin of 0.57%.The business had revenue of $129.86 million during the quarter, compared to analyst estimates of $118.85 million. Sell-side analysts anticipate that Arcutis Biotherapeutics, Inc. will post 0.16 earnings per share for the current fiscal year.

About Arcutis Biotherapeutics

Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for immuno-inflammatory skin diseases. The company’s research and development efforts center on targeted treatments that address the underlying biology of conditions such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis and vitiligo. Arcutis employs a precision-medicine approach to deliver topical therapies designed to improve efficacy and tolerability compared with existing treatment options.

In August 2022, Arcutis received U.S.